Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie is one of the most prominent biotechnology/healthcare stocks known for paying a good dividend. Besides the dividend, AbbVie didn't generate any returns on a one-year basis and is still a bit away from its all-time high.

AbbVie: Comparing The Current Valuation To Its Last Growth Cycle

Abbott Labs

Becton, Dickinson and Co.

Cardinal Health

Johnson & Johnson

Medtronic

Roper Technologies

West Pharmaceutical Services

While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Healthcare Stocks With at Least 30 Years of Dividend Increases

AbbVie is down about 8% YTD and appears undervalued at 13 times earnings. Dividend coverage looks strong based on both Free Cash Flow and Earnings Per Share.

AbbVie: A 4% SWAN Stock

AbbVie's Humira sales may hold up better against biosimilars in the USA than they have in Europe. The pharmaceutical giant has a diverse portfolio of blockbuster drugs that should help to offset declining revenues in its leading therapies.

Weather The Fed With AbbVie's Strong Portfolio And Solid Dividend Growth

Apple

Air Products and Chemicals

Caterpillar

Colgate-Palmolive

Clorox

General Dynamics

General Mills

Hormel Foods

Procter & Gamble

Starbucks

AT&T

AT&T 5.35 % Notes 2017-01.11.66 Global

Verizon

The system is clearly broken and has been for a while; however, I could find comfort in one thing, my dividends. These days, there are no shortages of accidental high yielding stocks but look at real cash on hand when viewing balance sheets.

DivHut Portfolio Update: February 2023

With the collapse of SVB Financial Group dominating the news and sending shockwaves again, we should look at recession-resilient companies like AbbVie. In fiscal 2022, AbbVie reported solid results, but growth slowed down.

AbbVie: With Banks In Distress, Look At Recession-Resilient Healthcare Companies

The collapse of SVB Financial Group shook stocks yet again, leaving investors wondering what comes next. While the market has a case of the jitters, this stock has a calming effect.

Is AbbVie Stock Safe In A Jittery Market?

-  More than 20 abstracts, including one late-breaking presentation, underscore AbbVie's dedication to advancing care for dermatologic conditions NORTH CHICAGO, Ill. , March 13, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21, in New Orleans, Louisiana.

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

Amgen

Ares Capital

BlackRock Taxable Municipal Bond Trust

BlackRock Science & Technology

Digital Realty Trust

iShares MSCI EAFE Growth ETF

iShares MSCI EAFE Value ETF

Fastenal

Flaherty & Crumrine Preferred Securities Income Fund Inc

Home Depot

Kimberly-Clark

Lockheed Martin

McDonald's

Magellan Midstream Partners

Altria

NextEra Energy

PIMCO Dynamic Income Fund

Cohen & Steers Quality Income Realty Fund

iShares 1-3 Year Treasury Bond ETF

Proshares Short 20+ Year Treasury

abrdn World Healthcare Fund 

iShares 20+ Year Treasury Bond ETF

The stock market is inherently volatile. With the economy going through the boom and bust cycles more frequently, the extreme ups and downs of the market are inevitable. For most conservative investors, especially retirees, it's very difficult to tolerate large and deep drawdowns. However, it is almost impossible to avoid these issues with index investing.

The Near-Perfect Portfolio: Sleep Well During Turbulent Times

Pfizer

The picture for AbbVie is better than meets the eye, despite declining sales for its top-selling drug Humira. Johnson & Johnson's impressive dividend streak should continue.

3 No-Brainer Dividend Stocks to Buy in March

Coca-Cola

Exxon Mobil

While most stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get paid monthly if they position themselves carefully. Who doesn't like payday?

Reap Monthly Income With This Combination of 3 Stocks

Green Thumb Industries Inc.

Tilray Brands

AbbVie is an income and growth stock with excellent long-term prospects. Green Thumb Industries has quadrupled its revenue since 2019.

3 Surefire Stocks That Are Screaming Buys in March

Ally Financial

Medical Properties Trust

Medical Properties Trust is a real estate investment trust that offers a huge 11.5% dividend yield. Ally Financial is an all-digital bank that offers a 4.1% yield at the moment.

3 High-Yield Dividend Stocks to Buy Before the Next Bull Rally

AbbVie expects U.S. sales of its blockbuster immunology drug Humira to decline 37% this year, as competition eats away at market share. But AbbVie's two newer immunology drugs could soon take over where Humira is leaving off.

Is It Too Late to Buy AbbVie Stock?

NEW PARTNERSHIP PROVIDES TRANSFORMATIVE GRANTS TO EMPOWER CONFIDENCE IRVINE, Calif. , March 8, 2023 /PRNewswire/ -- In honor of International Women's Day, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced that BOTOX® Cosmetic is partnering with IFundWomen, the go-to funding marketplace for women-owned businesses, on a grant program.

BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs

NORTH CHICAGO, Ill. , March. 8, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023.

AbbVie to Present at the Barclays Global Healthcare Conference

AbbVie Inc. (NYSE:ABBV ) Cowen 43rd Annual Healthcare Conference Call March 7, 2023 9:10 AM ET Company Participants Roopal Thakkar - Senior Vice President, Development and Regulatory Affairs and Chief Medical Officer Robert Michael - Vice Chairman and President Jeffrey Stewart - Executive Vice President and Chief Commercial Officer Conference Call Participants Stephen Scala - Cowen and Company, LLC Stephen Scala [Call Starts Abruptly] Cowen conference again this year. We have four members of management.

AbbVie Inc. (ABBV) Cowen 43rd Annual Healthcare Conference (Transcript)

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Apollo Commercial Real Estate Finance

Broadcom

Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets have started the new year with very solid gains following expectations about a more dovish Federal Reserve and a solid earnings season.

My Dividend Stock Portfolio: New February Record - 99 Holdings With 32 Buys And 4 Sales

News for AbbVie Stock (ABBV)